Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Sep 17.

Published in final edited form as: Mol Cancer Ther. 2016 Jun 20;15(9):2251–2258. doi: 10.1158/1535-7163.MCT-15-0908

Table 4.

Response, PFS, and OS by pretreatment intratumoral gene expression

		RECIST response			PFS			OS
Gene	n	Yes	No	P^a	Median (95% CI)	HR (95% CI)^b	P^a	Median (95% CI)	HR (95% CI)^b	P^a
TS^c				0.61			0.29			0.20
≤4.1	29	4 (14%)	25 (86%)		3.0 (1.7–4.4)	1 (Ref)		11.6 (5.4–15.4)	1 (Ref)
>4.1	9	2 (22%)	7 (78%)		4.3 (3.0–8.6)	0.64 (0.27–1.51)		7.8 (2.0–12.9)	1.68 (0.72–3.88)
DPD^d				0.55			0.38^b			0.66
≤0.86	27	6 (22%)	21 (78%)		3.0 (2.9–5.3)	1 (Ref)		7.8 (5.4–14.7)	1 (Ref)
>0.86	5	0 (0%)	5 (100%)		1.7 (1.5–1.7)	2.76 (0.67–11.41)		16.1+ (2.3–16.1+)	0.72 (0.17–3.11)
EGFR/HER1^c				0.65			0.097			0.74
≤1.19	11	1 (9%)	10 (91%)		3.0 (1.7–4.3)	1 (Ref)		14.8 (3.8–16.9)	1 (Ref)
>1.19	26	5 (19%)	21 (81%)		4.2 (2.6–5.8)	0.54 (0.24–1.24)		7.8 (4.2–14.7)	1.15 (0.50–2.63)
HER2^c				1.00			0.30			0.92
≤0.065	25	5 (20%)	20 (80%)		4.3 (2.9–5.7)	1 (Ref)		11.4 (4.2–14.7)	1 (Ref)
>0.065	8	1 (13%)	7 (88%)		2.6 (1.6–4.3)	1.55 (0.63–3.81)		5.4 (2.0–16.9)	0.96 (0.39–2.33)
HER3^d				0.008			0.11^d			0.75
≤4.51	19	0 (0%)	19 (100%)		3.0 (1.6–4.3)	1 (Ref)		6.3 (3.5–15.4)	1 (Ref)
>4.51	18	6 (33%)	12 (67%)		4.3 (3.0–8.6)	0.40 (0.18–0.91)		11.4 (7.2–15.9)	0.89 (0.42–1.88)

^a

Based on Fisher exact test for response and log-rank test for PFS and OS.

^b

Based on the method described by Berry and colleagues (38).

^c

The cut-off value of gene expression was based on our previous studies (31, 38, 47).

^d

The cut-off value was based on the optimal cut-off point for PFS and P values were adjusted accordingly (48).